Company Overview and News

 
VINCI : INFORMATION TRIMESTRIELLE AU 31 MARS 2018

2018-04-26 globenewswire
Les données d'activité du premier trimestre 2018, en dépit de conditions climatiques difficiles en Europe, confirment les bonnes tendances observées en 2017 et confortent la perspective de hausses du chiffre d'affaires et des résultats du Groupe pour l'ensemble de l'année.
SWL DG

 
UAE fund Mubadala in talks for Odebrecht-run rail operator Supervia- sources

2018-03-15 reuters
SAO PAULO (Reuters) - United Arab Emirates’ sovereign wealth fund Mubadala Development Co [MUDEV.UL] is keen to acquire a majority stake in Brazilian suburban rail operator Supervia, controlled by conglomerate Odebrecht SA, three sources with knowledge of the matter said.
DG

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to EPA:DG / VINCI on message board site Silicon Investor.

BTDG - B2Digital, Inc. BTDG - B2Digital, Inc. BTDG - B2Digital, Inc. The Beaver Lodge The Beaver Lodge The Beaver Lodge
Cloud, edge and decentralized computing Cloud, edge and decentralized computing Cloud, edge and decentralized computing Binary Hodgepodge Binary Hodgepodge Binary Hodgepodge
Smartphones, Tablets, Wearables and Gadgets Smartphones, Tablets, Wearables and Gadgets Smartphones, Tablets, Wearables and Gadgets Bridging weather and climate Bridging weather and climate Bridging weather and climate
Real Estate ETFs and REITs: Time to Hedge the Homestead? Real Estate ETFs and REITs: Time to Hedge the Homestead? Real Estate ETFs and REITs: Time to Hedge the Homestead? Naked Shorting-Hedge Fund u0026 Market Maker manipulation? Naked Shorting-Hedge Fund u0026 Market Maker manipulation? Naked Shorting-Hedge Fund u0026 Market Maker manipulation?
DG: Dollar General Corp. DG: Dollar General Corp. DG: Dollar General Corp. Knowledge Extraction Technologies Knowledge Extraction Technologies Knowledge Extraction Technologies